News
Vertex said it's gathering momentum with its new product launches, building out new franchises with its sickle cell therapy ...
Several members of an FDA advisory committee warned on Monday that new data from studies on long-term use of opioids might ...
Function Health is buying Ezra in a bid to create a haven for people who want copious amounts of data on their bodies. The ...
Bristol Myers Squibb is letting go of 516 workers in New Jersey as part of a wide-reaching cost-cutting plan aimed at making ...
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Deerfield Management is back with its third healthcare venture fund, this time securing more than $600 million to create new ...
Initial clinical data from Genocury and EsoBiotec shows promise for in vivo CAR-T therapy, with complete remission in ...
J&J's gene therapy bota-vec failed Phase 3 trial for X-linked retinitis pigmentosa vision loss. Follows trend of big pharma ...
FDA delays Stealth BioTherapeutics PDUFA date amid questions about agency disruption, while other companies like Sanofi and J ...
Not many would argue that Biotech is one of the riskiest industries on the globe. With costs hovering in the hundreds of millions of dollars, competitors ...
Flagship Pioneering has recruited Rahul Kakkar to lead its genetics-based drug discovery startup Quotient Therapeutics.
Vertex is pulling back on its genetic medicine research, ending all work related to adeno-associated viruses, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results